Recent Company News

• 08:10 AM ET Jun 30, 2025
  

  Chemomab Therapeutics announces oral presentation of Nebokitug Phase 2 clinical data in primary Sclerosing Cholangitis at BSG Live'25 ($1.17, 0.00)

• 08:04 AM ET Jun 11, 2025
  

  Chemomab Therapeutics announces positive feedback from two recent FDA meetings ($1.30, 0.00)

• 08:06 AM ET Jun 03, 2025
  

  Chemomab announces new patent awards for nebokitug in China and Russia ($1.35, 0.00)

• 08:04 AM ET May 15, 2025
  

  Chemomab Therapeutics reports Q1 EPS $0.01 vs FactSet ($0.10) [2 est, ($0.18)-(0.01)] ($1.21, 0.00)

• 08:12 AM ET May 05, 2025
  

  Chemomab announces presentation of nebokitug phase 2 clinical data in primary sclerosing cholangitis in distinguished plenary session at DDW 2025 ($1.42, 0.00)

• 08:08 AM ET Apr 28, 2025
  

  Chemomab reports new clinical data on nebokitug in primary sclerosing cholangitis and related diseases at EASL 2025 ($1.31, 0.00)

• 08:06 AM ET Apr 15, 2025
  

  Chemomab Therapeutics appoints David Weiner as Interim Chief Medical Officer, Jack Lawler as Chief Development Officer ($1.18, 0.00)

• 09:16 AM ET Mar 27, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:32 AM ET Mar 27, 2025
  

  Chemomab Therapeutics announces results from the Open Label Extension (OLE) portion of the Phase 2 SPRING trial ($1.16, 0.00)

• 08:12 AM ET Mar 06, 2025
  

  Chemomab Therapeutics announces presentation of nebokitug data ($1.40, 0.00)